Population Pharmacokinetic, Exposure-Response Efficacy and Safety Analyses of Favezelimab in Patients With Solid Tumors.

Mitali Gaurav¹, Heather Barcomb¹, Kelly F Maxwell¹, Bhargava Kandala², Manash S Chatterjee²

¹Clinical Pharmacology and Pharmacometric Solutions, Simulations Plus, Inc, Research Triangle Park, North Carolina, USA.

²Merck & Co., Inc, Rahway, New Jersey, USA.

PubMed PMC DOI PDF

Abstract

Favezelimab (MK-4280) is a humanized monoclonal antibody (mAb) targeting lymphocyte activation gene-3 (LAG-3). Favezelimab population pharmacokinetics (popPK) was evaluated using data from 2 trials; a Phase 1 study evaluating favezelimab across a range of doses (7 to 800 mg administered intravenously [IV] every 3 weeks [Q3W]) in patients with advanced solid tumors, and a Phase 3 study evaluating 8…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.